# Tempus AI to Acquire Genomics Company Personalis for $1.5 Billion

> ma · REPORTED · 2026-07-20

On July 20, 2026, Tempus AI and Personalis announced a definitive acquisition agreement at $16.25 per share, representing a total enterprise value of $1.5 billion, with the deal expected to close in late 2026 or early 2027. The acquisition integrates Personalis's tumor-informed minimal residual disease technology with Tempus's AI-enabled precision oncology platform.

About Tempus AI / Personalis: Tempus AI is a technology company deploying artificial intelligence to advance precision medicine and patient care, offering genomic testing, clinical data, and AI analytics to oncology clinicians and biopharma.

- Company: Tempus AI / Personalis
- Sector: genomics
- Primary source: https://www.mobihealthnews.com/news/tempus-ai-acquire-personalis-15b

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.